Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetragastrin SCHEMBL31332160 | 1.00 | CCKBR (0.70) | CCKBRCCKAR | |
| Tetragastrin SCHEMBL30999517 | 1.00 | CCKBR (0.70) | CCKBRCCKAR | |
| Tetragastrin SCHEMBL30999542 | 1.00 | CCKBR (0.70) | CCKBRCCKAR | |
| Tetragastrin SCHEMBL30999571 | 1.00 | CCKBR (0.70) | CCKBRCCKAR | |
| Tetragastrin SCHEMBL9710788 | 1.00 | CCKBR (0.70) | CCKBRCCKAR | |
| Tetragastrin SCHEMBL30999635 | 1.00 | CCKBR (0.70) | CCKBRCCKAR | |
| SCHEMBL18054010 | 1.00 | CCKBR (0.70) | CCKBRCCKAR | |
| Tetragastrin SCHEMBL30999572 | 1.00 | CCKBR (0.70) | CCKBRCCKAR | |
| Tetragastrin SCHEMBL11568902 | 0.99 | CCKBR (0.70) | CCKBRCCKAR | |
| SCHEMBL30999567 | 0.95 | CCKBR (0.66) | CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090492-A1 | TUMOR-ACTIVATED CELL ENGAGERS AND METHODS OF USE THEREOF | Xilio Development, Inc. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4644563-A1 | IN SITU SEQUENCING LIBRARY CONSTRUCTION METHOD, IN SITU SEQUENCING METHOD, AND USE | BGI Shenzhen (CN) | 2025-11-05 | — | — | EP | claimed |
| US-20240238378-A1 | METHODS AND CCK-B RECEPTOR AGONISTS FOR TREATING TINNITUS | CITY UNIVERSITY OF HONG KONG (HK) | 2024-07-18 | — | — | US | claimed |
| CN-118304408-A | Methods and CCK-B receptor agonists for treating tinnitus | 香港城市大学 | 2024-07-09 | — | — | CN | claimed |
| WO-2024138347-A1 | IN SITU SEQUENCING LIBRARY CONSTRUCTION METHOD, IN SITU SEQUENCING METHOD, AND USE | 深圳华大生命科学研究院 | 2024-07-04 | — | — | WO | claimed |
| WO-2023174433-A1 | SOLID, SEMISOLID, OR LIQUID COMPOSITIONS FOR AUGMENTING THE STABILITY, PERMEABILITY AND BIOAVAILABILITY OF ACTIVE PHARMACEUTICAL SUBSTANCES | Smart Pharmaceutical (Suzhou) Co., Ltd. (CN) | 2023-09-21 | — | — | WO | claimed |
| WO-2023135398-A1 | ANTIBODY-DRUG CONJUGATES FOR THERAPEUTIC USE | MC SAF (FR) | 2023-07-20 | — | — | WO | claimed |
| US-11278627-B2 | Antibody-drug conjugates and the use of same in therapy | MC SAF (FR) | 2022-03-22 | — | — | US | claimed |
| WO-1992019253-A1 | CCK ANALOGS CONTAINING α-SUBSTITUTED AMINO ACIDS | WARNER-LAMBERT COMPANY (US) | 1992-11-12 | — | — | WO | claimed |
| US-4794103-A | Pharmaceutical compositions containing peptides of the cholecystokinin-cerulein group for the therapy of shock conditions and of respiratory and cardiocirculatory insufficiencies | BERTOLINI ALFIO (IT) | 1988-12-27 | — | — | US | claimed |
| WO-2026102462-A1 | ENGINEERED CELLS FOR TREATING DIABETES | CITY OF HOPE (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4735047-A1 | PEGYLATED LINKERS AND USES THEREOF | Université de Tours (FR) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735046-A1 | BIOCONJUGATION SYSTEMS AND USES THEREOF | Université de Tours (FR) | 2026-05-06 | — | — | EP | disclosed |
| US-12617815-B2 | Barcoded XTEN polypeptides and compositions thereof, and methods for making and using the same | AMUNIX PHARMACEUTICALS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| WO-2026090492-A1 | TUMOR-ACTIVATED CELL ENGAGERS AND METHODS OF USE THEREOF | Xilio Development, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-0405506-A1 | Tetrapeptide type-B CCK receptor ligands | ABBOTT LABORATORIES (US) | 1991-01-02 | — | — | EP | disclosed |
| EP-0115227-B1 | PEPTIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1987-03-18 | — | — | EP | disclosed |
| US-4530837-A | Containing tryptophan | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1985-07-23 | — | — | US | disclosed |
| EP-0115227-A1 | Peptide derivatives, process for their preparation and their pharmaceutical use | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1984-08-08 | — | — | EP | disclosed |
| US-4164571-A | Medicament which antagonizes the action of gastrin and related polypeptides | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1979-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617815-B2 | Barcoded XTEN polypeptides and compositions thereof, and methods for making and using the same | SPPL2B, PTMS, ANPEP | CCKBR 532/4885CCKAR 1274/4885 |
| US-20240238378-A1 | METHODS AND CCK-B RECEPTOR AGONISTS FOR TREATING TINNITUS | CCKBR, CCKAR, NTSR2 | CCKBR 1/4885CCKAR 2/4885 |
| US-11278627-B2 | Antibody-drug conjugates and the use of same in therapy | CD47, TNFRSF9, VSIG8 | CCKBR 4292/4885CCKAR 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.